यूरोपीय संघ - स्वीडिश - EMA (European Medicines Agency)

mylan ire healthcare limited - pretomanid - tuberkulos, multidrug-resistent - medel mot mykobakterier - dovprela is indicated in combination with bedaquiline and linezolid, in adults, for the treatment of pulmonary extensively drug resistant (xdr), or treatment-intolerant or nonresponsive multidrug-resistant (mdr) tuberculosis (tb). hänsyn bör tas till officiella riktlinjer för lämplig användning av antibakteriella medel.

यूरोपीय संघ - स्वीडिश - EMA (European Medicines Agency)

biocryst ireland limited - berotralstat dihydrochloride - angioödemar, ärftlig - other hematological agents - orladeyo is indicated for routine prevention of recurrent attacks of hereditary angioedema (hae) in adult and adolescent patients aged 12 years and older.

स्वीडन - स्वीडिश - Läkemedelsverket (Medical Products Agency)

viatris limited - apixaban - filmdragerad tablett - 5 mg - laktosmonohydrat hjälpämne; natriumlaurilsulfat hjälpämne; apixaban 5 mg aktiv substans; laktos (vattenfri) hjälpämne

स्वीडन - स्वीडिश - Läkemedelsverket (Medical Products Agency)

viatris limited - apixaban - filmdragerad tablett - 2,5 mg - natriumlaurilsulfat hjälpämne; laktosmonohydrat hjälpämne; laktos (vattenfri) hjälpämne; apixaban 2,5 mg aktiv substans

यूरोपीय संघ - स्वीडिश - EMA (European Medicines Agency)

mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - diabetes mellitus, typ 2 - läkemedel som används vid diabetes - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. - , trippel kombinationsterapi) som ett komplement till kost och motion hos patienter bristfälligt kontrollerad på deras maximal tolererad dos av metformin och en sulphonylurea. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

यूरोपीय संघ - स्वीडिश - EMA (European Medicines Agency)

mylan ireland limited - dimetylfumarat - multipel skleros, skovvis förlöpande - immunsuppressiva - dimethyl fumarate mylan is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

यूरोपीय संघ - स्वीडिश - EMA (European Medicines Agency)

mylan pharmaceuticals limited - teriflunomide - multipel skleros, skovvis förlöpande - immunsuppressiva - teriflunomide mylan is indicated for the treatment of adult patients and paediatric patients aged 10 years and older (body weight > 40 kg) with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 of the smpc for important information on the population for which efficacy has been established).

यूरोपीय संघ - स्वीडिश - EMA (European Medicines Agency)

novartis europharm limited  - gozetotide - radionuklid imaging - diagnostiska radioaktiva läkemedel - detta läkemedel är endast för diagnostisk användning. locametz, after radiolabelling with gallium 68, is indicated for the detection of prostate specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high risk pca prior to primary curative therapy,suspected pca recurrence in patients with increasing levels of serum prostate specific antigen (psa) after primary curative therapy,identification of patients with psma positive progressive metastatic castration resistant prostate cancer (mcrpc) for whom psma targeted therapy is indicated (see section 4.

स्वीडन - स्वीडिश - Läkemedelsverket (Medical Products Agency)

viatris limited - beklometasondipropionat (vattenfritt); formoterolfumaratdihydrat - inhalationsspray, lösning - 100 mikrogram/6 mikrogram/dos - etanol, vattenfri hjälpämne; beklometasondipropionat (vattenfritt) 100 mikrog aktiv substans; formoterolfumaratdihydrat 6 mikrog aktiv substans

यूरोपीय संघ - स्वीडिश - EMA (European Medicines Agency)

viatris limited - dapagliflozin - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - läkemedel som används vid diabetes - type 2 diabetes mellitusdapagliflozin viatris is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise- as monotherapy when metformin is considered inappropriate due to intolerance. - in addition to other medicinal products for the treatment of type 2 diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 och 5. heart failuredapagliflozin viatris is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction. chronic kidney diseasedapagliflozin viatris is indicated in adults for the treatment of chronic kidney disease.